Clinical trials: Terminal Illness
Kidney Failure, Chronic, Renal Disease, End-Stage
Pharmacokinetics/Pharmacodynamics of Argatroban Injection in End-Stage Renal Disease Patients Undergoing Hemodialysis
The primary goals of this investigation are to provide guidance on how to dose Argatroban in patients undergoing hemodialysis and to assess the safety and tolerability of Argatroban in hemodialysis patients.
- Trial name
- NCT00035178
- Testing
- Argatroban
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Texas Biotechnology Corporation
Kidney Failure, Chronic
A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialysis
This is a multi-center, two-part study; Part A and Part B. Part A of the study is an open-label, single-dose pharmacokinetic (PK) evaluation of 100 mg RVX000222 on dialysis and non-dialysis days in eight (8) End Stage Renal…
- Trial name
- NCT03160430
- Testing
- apabetalone
- Volunteers
- 44 people
- Sponsor
- Resverlogix Corp
Renal Disease, End Stage
PK Study of IV and Oral Amisulpride in Subjects With Severe Renal Impairment
The aim of the study is to understand how Amisulpride is taken up and distributed around the body and how quickly it is eliminated, when given by mouth and into a vein in adults with severe kidney disease.
- Trial name
- NCT04849650
- Testing
- Amisulpride IV, Amisulpride Oral Tablet
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Acacia Pharma Ltd
Terminal Illness, End-of-Life Care
Non-Invasive Detection and Preservation of Neurocognitive Signals in the Peri-Death Period Using Brain-Computer Interface and Artificial Intelligence
Background: Recent electroencephalography (EEG) data indicate that the transition from clinical death to cellular death is marked by highly organized neurophysiological events, including significant surges in gamma-band power…
- Conditions
- Terminal Illness, End-of-Life Care, Death, Brain Death
- Trial name
- NeuroCogPresv (NCT07477028)
- Volunteers
- 20 people
- Sponsor
- Noah Tech, Corp.
Terminal Illness
Open-Label Treatment Extension of Protocol MNTX 302
This is a 3 month open-label extension study that allows patients who completed Protocol MNTX 302 to receive SC MNTX.
- Trial name
- NCT01367613
- Testing
- SC Methylnaltrexone
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Bausch Health Americas, Inc.
Kidney Disease, End-Stage
PATH-03 Paraguay Feasibility Study
The goal of this study is to evaluate the safety and effectiveness of the ePATH system in the creation of an endovascular AVF (endoAVF) in patients who require or will soon require hemodialysis and are eligible for a fistula.
- Trial name
- NCT07034092
- Testing
- ePATH System will be used to create an endoAVF
- Where
- Paraguay
- Volunteers
- 20 people
- Sponsor
- Pathfinder Medical
Renal Disease, Chronic, Renal Disease, End-Stage
Non-invasive Testing for End-Stage Chronic Kidney Disease
This study evaluates the clinical performance of a non-invasive digital diagnostic test (KF4+, developed and manufactured by Gisens Biotech) for the measurement of urea and potassium in capillary blood in patients with end-stage…
- Conditions
- Renal Disease, Chronic, Renal Disease, End-Stage, Dialysis Patients, Urea in Blood; High
- Trial name
- NiTED (NCT07777523)
- Testing
- KF4+ Noninvasive Test
- Where
- Argentina
- Volunteers
- 55 people
- Sponsor
- Gisens Biotech
Terminal Illness
Open-Label Treatment Extension of Protocol MNTX 301
This study is an open-label extension allowing patients who have completed Protocol MNTX 301 to continue to receive SC MNTX.
- Trial name
- NCT01367600
- Testing
- SC Methylnaltrexone (MNTX)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Bausch Health Americas, Inc.
Renal Disease, End Stage, Kidney Disease, End-Stage
Ellipsys Vascular Access System Post Market Surveillance (PS) Study
The proposed clinical study is a prospective, non-randomized, multi-center, single-arm, observational, post-market surveillance (PS) study of the Ellipsys Vascular Access System in subjects eligible for arteriovenous (AV) fistula.
- Conditions
- Renal Disease, End Stage, Kidney Disease, End-Stage, AV Fistula, Fistulas Arteriovenous
- Trial name
- NCT04484220
- Testing
- Ellipsys Vascular Access System
- Where
- 12 sites in United States
- Volunteers
- 142 people
- Sponsor
- Medtronic Endovascular
Anemia
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis
The purpose of this study is to evaluate whether hemodialysis patients on peginesatide can be converted to epoetin alfa by using a predefined conversion table while achieving a stable hemoglobin.
- Trial name
- NCT01737879
- Testing
- Peginesatide, Epoetin alfa
- Where
- 23 sites in United States
- Volunteers
- 41 people
- Sponsor
- Amgen
Renal Disease, End-Stage, Renal Insufficiency, Chronic
Bosutinib In Subjects With Renal Impairment
This is a two-staged study of a single dose of 200 mg of bosutinib given to subjects with renal impairment and matching healthy volunteers.
- Conditions
- Renal Disease, End-Stage, Renal Insufficiency, Chronic, Renal Insufficiency, Acute
- Trial name
- NCT01233882
- Testing
- Bosutinib
- Where
- 5 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Pfizer
Kidney Failure,Chronic, Renal Insufficiency,Chronic
Determination In-vivo KUF for Diacap Pro Hemodialyser
The main purpose of this study is the determination of the in-vivo ultrafiltration coefficient (in-vivo KUF) for Diacap Pro dialyzers following routine dialysis prescription in the United States.
- Conditions
- Kidney Failure,Chronic, Renal Insufficiency,Chronic, Kidney Disease, End-Stage, Kidney Insufficiency
- Trial name
- NCT02964429
- Testing
- Diacap Pro High-Flux
- Where
- Czechia
- Volunteers
- 12 people
- Sponsor
- B.Braun Avitum AG
Kidney Disease, End-Stage, End-stage Renal Disease
Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
A prospective, single-arm, multi-center post-market surveillance study of the BD® WavelinQ™ EndoAVF System for the Creation of Arteriovenous (AV) Fistula in Patients Requiring Dialysis.
- Conditions
- Kidney Disease, End-Stage, End-stage Renal Disease, Arteriovenous Fistula
- Trial name
- CONNECT-AV (NCT04634916)
- Testing
- EndoAVF Creation
- Where
- 17 sites in United States, Australia
- Volunteers
- 220 people
- Sponsor
- C. R. Bard
Kidney Disease, End-Stage
Evaluating the Use of the Qidni/D Hemodialysis System by Subjects With End-Stage Renal Disease
The main goal of this clinical study is to evaluate the safety of the Qidni/D Hemodialysis System in patients with end-stage renal disease.
- Trial name
- NCT06086470
- Testing
- Qidni/D Hemodialysis System
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Qidni Labs Inc.